Alzheimer’s Phospho-Tau 217 Test
Specialist plasma p-Tau217 testing for adults aged 50+ with cognitive impairment being assessed for Alzheimer disease and other causes of decline.
Turnaround time
4 weeks
Biomarkers count
1
Book your test
Choose Service Type
Professional phlebotomist comes to you
+ £{{ home_visit_fee }}
Visit our clinic for your test
{{ clinic_visit_fee > 0 ? '+ £' + clinic_visit_fee : '+ £0' }}
Home Visit Details
Home visits require at least 24 hours notice.
Select a clinic: Sorting by distance…
{{ clinicAddress(clinic) }}
{{ clinicAddress(selectedClinic) }}
Select a date
Select an hour
Available time slots: {{ timeSlots.length}}
Overview of the Alzheimer’s Phospho-Tau 217 Test
The Alzheimer’s Phospho-Tau 217 Test is a specialist plasma blood test measuring phosphorylated Tau 217, or p-Tau217, a biomarker associated with neuropathological changes seen in Alzheimer disease.
This test is intended for adults aged 50 years and over who already have cognitive impairment and are undergoing assessment for Alzheimer disease or other causes of cognitive decline.
It should not be used as a general screening test in people without cognitive symptoms and should not be used to predict whether an asymptomatic person will develop dementia in the future.
p-Tau217 results are interpreted alongside clinical history, neurological examination, cognitive assessment and, where required, imaging or cerebrospinal-fluid biomarkers.
The test does not independently establish the severity of disease and has not been established as a method for monitoring the response to disease-modifying treatment.
Kidney function is also relevant because chronic kidney disease can affect p-Tau217 concentrations and may complicate interpretation.
The Alzheimer’s Phospho-Tau 217 Test costs £280.
The sample has specialist processing requirements, so collection must be arranged through a pathway that can prepare and freeze the plasma within the required timeframe.
What Does the Alzheimer’s Phospho-Tau 217 Test Check?
This test measures 1 specialist neurological biomarker.
Phospho-Tau 217 (p-Tau217)
Measures phosphorylated Tau at position 217 in plasma, a biomarker associated with Alzheimer-related amyloid and tau neuropathology when interpreted in the appropriate clinical context.
Who May Benefit From the Alzheimer’s Phospho-Tau 217 Test?
The test is intended for a specific clinical population rather than general cognitive-health screening.
Adults aged 50 or over with established cognitive impairment - p-Tau217 can contribute to assessment of whether Alzheimer-related pathology may be associated with the symptoms.
People undergoing investigation for memory or cognitive decline - The result may add information to neurological and cognitive assessment.
People whose clinician is differentiating possible causes of cognitive impairment - p-Tau217 may contribute to the wider diagnostic pathway.
People being considered for further amyloid-related investigation - The result may help determine whether PET imaging or cerebrospinal-fluid testing is appropriate.
People already under neurological, memory-clinic or specialist assessment - p-Tau217 can provide an additional blood-based biomarker.
How to Prepare
The sample requires specialist processing after collection.
Plasma must be separated and frozen within the required timeframe, so the appointment must be arranged through a collection pathway capable of meeting these requirements.
Symptoms and Reasons to Consider the Alzheimer’s Phospho-Tau 217 Test
The test should be considered in the context of established cognitive symptoms rather than as preventive screening in well individuals.
Progressive memory difficulty - Persistent memory changes may require formal cognitive assessment.
Difficulty finding words or following conversations - Language changes can occur in several neurological conditions.
Increasing difficulty managing familiar tasks - Functional cognitive change warrants medical assessment.
Changes in orientation or navigation - New difficulty with familiar places should be clinically investigated.
Progressive cognitive decline noticed by family or carers - Objective assessment can help establish whether further investigation is needed.
A specialist has recommended Alzheimer-related biomarker testing - This is the most appropriate context for p-Tau217 assessment.
This test is not intended to predict future Alzheimer disease in people who are cognitively normal.
New confusion, sudden speech difficulty, facial weakness, limb weakness or other acute neurological symptoms require urgent medical assessment because these can indicate conditions such as stroke rather than a chronic neurodegenerative process.
How to Book Your Alzheimer’s Phospho-Tau 217 Test
The Alzheimer’s Phospho-Tau 217 Test requires specialist plasma processing and should be arranged through London Blood Tests before collection.
Choose the Alzheimer’s Phospho-Tau 217 Test
Select the £280 specialist neurological biomarker test.
Select your collection option
In-clinic phlebotomy is +£35. At-home phlebotomy is +£60 only where the required rapid plasma processing and freezing can be arranged.
Attend your appointment
A trained healthcare professional collects the required blood specimen.
Laboratory analysis
Plasma is prepared according to the specialist handling requirements and p-Tau217 is measured.
Receive your results securely
Your authorised result is delivered securely for appropriate clinical interpretation.
When Will I Receive My Results?
Results are generally expected within approximately 4 weeks after the correctly prepared specimen reaches the laboratory.
This is a specialist neurological biomarker assay and therefore has a longer turnaround than routine blood testing.
Understanding Your Results
Results are interpreted using the assay-specific reporting categories.
A negative p-Tau217 result is consistent with a reduced likelihood of the Alzheimer-related neuropathological changes that would typically produce an abnormal amyloid PET result.
An intermediate result cannot reliably distinguish whether Alzheimer-related neuropathological changes are present or absent. Additional assessment, such as amyloid PET imaging or cerebrospinal-fluid amyloid and tau biomarkers, may be required.
A positive result is consistent with the presence of Alzheimer-related neuropathological changes and may support Alzheimer disease as a cause of current cognitive symptoms when the wider clinical picture is compatible.
A positive result does not independently establish the diagnosis, measure disease severity or predict the future course of symptoms.
Kidney impairment and other clinical factors must also be considered.
Why Book With London Blood Tests?
London Blood Tests provides access to specialist plasma p-Tau217 testing with the required pre-analytical handling pathway.
Specialist Alzheimer-related biomarker - p-Tau217 provides biochemical information relevant to Alzheimer neuropathology.
Blood-based assessment - The marker is measured from plasma rather than requiring a lumbar puncture for the initial test.
Designed for symptomatic assessment - The test is used in adults aged 50+ who already have cognitive impairment.
Clear interpretation boundaries - The test is not presented as a predictive screen for healthy asymptomatic adults.
Specialist specimen handling - Collection is arranged to meet the required processing and freezing conditions.
Four-week turnaround - The specialist nature of the assay is reflected in the reporting timeframe.
Clear pricing - The Alzheimer’s Phospho-Tau 217 Test costs £280, with sample collection charged separately where applicable.
Private Alzheimer’s Phospho-Tau 217 Test in London
London Blood Tests provides private p-Tau217 testing for adults aged 50 or over with cognitive impairment who are undergoing assessment for Alzheimer disease and other causes of cognitive decline.
The test costs £280 and measures one specialist plasma biomarker.
The specimen requires specialist handling, and results are generally expected within approximately four weeks.